Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,082Revenue (TTM) $M191Net Margin (%)-38.9Altman Z-Score3.1
Enterprise Value $M5,851EPS (TTM) $-0.3Operating Margin %-14.7Piotroski F-Score6
P/E(ttm)--Beneish M-Score-0.2Pre-tax Margin (%)-38.9Higher ROA y-yY
Price/Book67.910-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsY
Price/Sales26.85-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow24.1y-y EBITDA Growth Rate %--ROA % (ttm)-15.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M291ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

EXEL is held by these investors:

EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hessekiel JeffreyEVP and General Counsel 2017-03-22Sell23,787$20.541.8view
FELDBAUM CARL BDirector 2017-03-20Sell10,000$21.77-3.95view
PAPADOPOULOS STELIOSDirector 2017-03-20Sell10,000$21.66-3.46view
WILLSEY LANCEDirector 2017-03-15Sell10,000$22.86-8.53view
Schwab GiselaPres Prod Dev & Med Aff & CMO 2017-03-15Sell50,007$22.53-7.19view
COHEN CHARLESDirector 2017-03-13Sell10,000$21.82-4.17view
MARCHESI VINCENT TDirector 2017-03-10Sell40,000$21.98-4.87view
MORRISSEY MICHAELPresident and CEO 2017-03-06Sell200,000$22.72-7.97view
Senner Christopher J.EVP and CFO 2017-03-03Sell11,000$22.8-8.29view
Hessekiel JeffreyEVP and General Counsel 2017-03-03Sell100,000$23.04-9.24view

Quarterly/Annual Reports about EXEL:

News about EXEL:

Articles On GuruFocus.com
Top Performing Contest Portfolios from 2016 Jan 17 2017 
7 Stocks Outperforming the Market Jan 12 2017 
Why You Should Be Using the Altman Z-Score Dec 18 2016 
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 

More From Other Websites
When Profit Makers Can Be Active Profit Takers Mar 16 2017
Coverage initiated on Exelixis by Oppenheimer Mar 16 2017
ETFs with exposure to Exelixis, Inc. : March 6, 2017 Mar 06 2017
Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma Mar 06 2017
EXELIXIS, INC. Financials Mar 03 2017
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales... Mar 03 2017
Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis Mar 02 2017
Exelixis Announces Webcasts of Investor Conference Presentations in March Mar 01 2017
M&As, Pipeline Catalysts to Drive Pharma Sector Mar 01 2017
Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017 Mar 01 2017
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals Mar 01 2017
Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Feb 28 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)